SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

About this update from Seastar Medical Holding Corporation

[{"type":"image","alt":"SeaStar Medical","displaySize":"","headline":null,"caption":"SeaStar Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/4c7240b3e0b5bc01bb2108fbeef0b4c6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LUjJFfXNTg2cjq9rPHCJQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4c7240b3e0b5bc01bb2108fbeef0b4c6","width":300,"height":110}},"lazy":false},{"type":"text","content":"Webcast Today at 4:30 pm Eastern Time","length":37,"tagName":"p"},{"type":"text","content":"DENVER, March 27, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2024, and provided business updates on key initiatives.","length":381,"tagName":"p"},{"type":"text","content":"“Our significant accomplishment in 2024 position us well for a transformational year in 2025,” said Eric Schlorff, SeaStar Medical CEO. “Last year, we not only received our first product approval for QUELIMMUNE and began our commercial launch, but we added 14 new clinical sites for our NEUTRALIZE AKI pivotal clinical trial, which has led to steady progress in enrollment with 94 of our anticipated 200 patients enrolled in the trial. We were also awarded our fourth Breakthrough Device Designation which should enable us to speed up the review and approval processes for our Selective Cytopheretic Device (SCD) therapy for these indications.”","length":644,"tagName":"p"},{"type":"text","content":"Mr. Schlorff continued, “And I am pleased to report that our momentum has continued this year. We have added new commercial customers and have a healthy pipeline of prospective customers in the process of adopting the QUELIMMUNE therapy. We activated two additional sites in our NEUTRALIZE AKI pivotal clinical trial, and the FDA approved a feasibility study for our SCD therapy as a treatment for cardiorenal syndrome as a bridge to left ventricular assist device. We secured additional capital to support planned operations and just last week the National Kidney Foundation announced that SeaStar Medical has been awa...

More updates from Seastar Medical Holding Corporation